After License Deal for Letermovir: Head-to-head Phase 2 Trial Initiated by AiCuris to Demonstrate Superiority of its Novel Drug Pritelivir vs. Valacyclovir for Treatment of Genital Herpes

WUPPERTAL, Germany, November 27, 2012 /PRNewswire/ –

Cross-Reference: More Informations are available at:

http://www.presseportal.de/pm/106935

AiCuris announced today that it has started the second clinical efficacy trial with
pritelivir (AIC316), its novel anti-herpes simplex virus (HSV) drug in development. After
the first trial showed a high efficacy of pritelivir against genital herpes, the present
trial AIC316-01-II-02 (NCT01658826, http://www.clinicaltrials.gov) is designed to
prove superiority of pritelivir vs. valacyclovir in reducing genital HSV shedding.

http://www.aicuris.com/10/News_Publications.htm

“We expect to see superior efficacy of pritelivir in direct comparison with
valacyclovir”, comments Dr. Alexander Birkmann, project leader for pritelivir. “Reduction
of viral shedding is not only extremely relevant for the patients to reduce the risk of
transmitting genital herpes to their partner, which is only reduced by 50% with present
therapies. It is also a predictor for the potency of pritelivir to treat or even prevent
the development of herpes lesions.” Furthermore, pritelivir offers very convenient dosing
regimens for patients: only one pill for treatment of a herpes episode.

About pritelivir

Pritelivir is a potent inhibitor of HSV replication. It has a new mode of action
(inhibition of the viral helicase-primase enzyme complex) and a favorably long plasma
half-life. It also stems from a novel chemical class. Pritelivir is active against both
labial and genital herpes virus strains and retains activity against viruses which have
become resistant to marketed drugs.

In the previous trial pritelivir exhibited a highly significant and dose dependent
reduction of viral shedding, of the amount of virus shed, and of clinical lesions under
treatment.

Contact:

http://www.Aicuris.com

AiCuris GmbH & Co. KG

        Katja Woestenhemke
        Friedrich-Ebert-Str. 475/Building 302
        42117 Wuppertal
        Phone:  +49-202-317-63-1176
        Fax:    +49-202-317-63-1177
        E-mail: press@aicuris.com

SOURCE AiCuris GmbH & Co. KG